Liou, Bo-HuangBo-HuangLiouCheng, Chih-NingChih-NingChengLin, Ya-TingYa-TingLinLin, Yu-JouYu-JouLinYU-CHUNG CHUANGKUAN-YIN LINLiu, Wen-ChunWen-ChunLiuSHU-WEN LINCHING-HUA KUOHSIN-YUN SUNCHIEN-CHING HUNG2022-05-252022-05-2520211758-2652https://scholars.lib.ntu.edu.tw/handle/123456789/612041Short-course preventive therapy with 1-month course of daily administration of isoniazid (300-mg) plus rifapentine (600-mg) (1HP) and 3-month course of weekly administration of isoniazid (900-mg) plus rifapentine (900-mg) (3HP) has higher completion rates than 9-month course of daily isoniazid (9H) for individuals with latent tuberculosis infection (LTBI). We aimed to evaluate the effect, safety and tolerability of 1HP in people living with HIV (PLWH) and LTBI who received coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).endrug-drug interaction; integrase strand transfer inhibitor; protein-adjusted 95% effective concentration; rifamycin; trough concentration[SDGs]SDG3journal article10.1002/jia2.25844348222202-s2.0-85119972384WOS:000727329800011https://scholars.lib.ntu.edu.tw/handle/123456789/589812